Fisher Asset Management LLC Sells 408 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fisher Asset Management LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,243 shares of the medical research company’s stock after selling 408 shares during the quarter. Fisher Asset Management LLC’s holdings in IQVIA were worth $1,213,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC increased its position in IQVIA by 3.6% during the third quarter. Commonwealth Equity Services LLC now owns 20,753 shares of the medical research company’s stock valued at $4,083,000 after acquiring an additional 726 shares during the last quarter. Brown Advisory Inc. boosted its holdings in shares of IQVIA by 11.8% in the third quarter. Brown Advisory Inc. now owns 1,688 shares of the medical research company’s stock worth $332,000 after buying an additional 178 shares during the last quarter. Advisor Partners II LLC grew its position in IQVIA by 47.8% during the third quarter. Advisor Partners II LLC now owns 5,903 shares of the medical research company’s stock valued at $1,161,000 after buying an additional 1,910 shares during the period. Park Avenue Securities LLC purchased a new stake in IQVIA during the third quarter valued at approximately $372,000. Finally, CENTRAL TRUST Co raised its position in IQVIA by 53.8% in the third quarter. CENTRAL TRUST Co now owns 620 shares of the medical research company’s stock worth $122,000 after acquiring an additional 217 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $229.20 on Friday. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The company has a market capitalization of $41.76 billion, a PE ratio of 31.31, a P/E/G ratio of 2.16 and a beta of 1.52. The company has a 50 day moving average price of $242.48 and a 200-day moving average price of $225.08. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the company earned $2.54 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several analyst reports. BTIG Research started coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI cut their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Truist Financial decreased their target price on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Finally, SVB Leerink started coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $257.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.